GlassScriptPhysician profile
Amy G Barth
NPI 1316155567
$9,199.30
in general payments reported to CMS, 2019-2025
49 companies · $1,593 in 2025
The $1,593 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,101 · 2022: $1,749 · 2023: $1,616 · 2024: $2,140 · 2025: $1,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,348.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,500.27 | 2021-2025 | |
| Novo Nordisk INC | $1,285.14 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,008.44 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $785.70 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $470.31 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $402.10 | 2021-2025 | |
| Abbott Laboratories | $362.92 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $310.12 | 2021-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.17 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $275.95 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $209.04 | 2021-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.97 | 2021-2025 | Jardiance |
| Exact Sciences Corporation | $206.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.91 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $132.43 | 2022-2023 | Veozah, Myrbetriq |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Barth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.